📊 ARMP Key Takeaways
Is Armata Pharmaceuticals, Inc. (ARMP) a Good Investment?
Armata Pharmaceuticals faces existential financial distress with negative stockholders equity of -$311.6M, indicating technical insolvency. The company generates negligible revenue ($31.0K) against operating losses of -$8.8M and negative operating cash flow of -$5.8M, creating an unsustainable burn rate with only $4.8M in cash reserves.
Armata Pharmaceuticals' fundamentals are extremely weak: revenue remains negligible relative to its cost base, operating and net losses are massive, and free cash flow is deeply negative. The balance sheet is highly stressed with negative equity and very poor liquidity, so despite headline revenue growth and improved EPS, the growth quality is low and the company appears heavily dependent on external financing.
Armata Pharmaceuticals, Inc. Key Strengths (ARMP)
- Minimal revenue base ($31.0K) shows early commercialization activity, albeit at negligible scale
- Recent Form 4 insider filings (12 in 90 days) indicate some management activity
- As a biotech company, potential for future pipeline value if capital constraints are resolved
- Revenue grew sharply year over year, indicating some commercial or collaboration progress from a very small base
- Diluted EPS improved meaningfully year over year, suggesting losses per share narrowed
- Asset base of $89.52M provides some operational runway relative to current scale
ARMP Stock Risks: Armata Pharmaceuticals, Inc. Investment Risks
- Negative stockholders equity of -$311.6M indicates permanent loss of shareholder capital and technical insolvency
- Critical liquidity crisis with current ratio of 0.64x; liabilities of $381.4M exceed assets of $69.8M by $311.6M
- Unsustainable burn rate with operating cash flow of -$5.8M against only $4.8M cash; limited runway without immediate capital injection
- Net losses of -$115.3M with operating margin of -28338.7%; no path to profitability evident from current fundamentals
- Interest coverage ratio of -1.9x indicates inability to service debt obligations from operations
- Negative stockholders equity and total liabilities far exceeding assets indicate severe balance sheet weakness
- Current and quick ratios of 0.12x signal acute near-term liquidity pressure
- Operating cash burn and free cash flow losses remain large versus cash on hand, raising funding risk
Key Metrics to Watch
- Cash runway and timeline to next financing event or bankruptcy filing
- Quarterly revenue trends and customer concentration
- Operating burn rate and operating cash flow improvement trajectory
- Quarterly operating cash burn relative to cash and equivalents
- Liquidity improvement through current ratio, equity rebuild, and liability reduction
Armata Pharmaceuticals, Inc. (ARMP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ARMP Profit Margin, ROE & Profitability Analysis
ARMP vs Healthcare Sector: How Armata Pharmaceuticals, Inc. Compares
How Armata Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Armata Pharmaceuticals, Inc. Stock Overvalued? ARMP Valuation Analysis 2026
Based on fundamental analysis, Armata Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Armata Pharmaceuticals, Inc. Balance Sheet: ARMP Debt, Cash & Liquidity
ARMP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Armata Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.89 indicates the company is currently unprofitable.
ARMP Revenue Growth, EPS Growth & YoY Performance
ARMP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2020 | $31.0K | -$4.2M | $-0.26 |
| Q1 2015 | $102.0K | -$11.3M | N/A |
| Q3 2014 | -$3.0K | $19.3M | $0.06 |
| Q2 2014 | $310.0K | $3.4M | $0.01 |
| Q1 2014 | N/A | -$1.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Armata Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ARMP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Armata Pharmaceuticals, Inc. (CIK: 0000921114)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARMP
What is the AI rating for ARMP?
Armata Pharmaceuticals, Inc. (ARMP) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARMP's key strengths?
Claude: Minimal revenue base ($31.0K) shows early commercialization activity, albeit at negligible scale. Recent Form 4 insider filings (12 in 90 days) indicate some management activity. ChatGPT: Revenue grew sharply year over year, indicating some commercial or collaboration progress from a very small base. Diluted EPS improved meaningfully year over year, suggesting losses per share narrowed.
What are the risks of investing in ARMP?
Claude: Negative stockholders equity of -$311.6M indicates permanent loss of shareholder capital and technical insolvency. Critical liquidity crisis with current ratio of 0.64x; liabilities of $381.4M exceed assets of $69.8M by $311.6M. ChatGPT: Negative stockholders equity and total liabilities far exceeding assets indicate severe balance sheet weakness. Current and quick ratios of 0.12x signal acute near-term liquidity pressure.
What is ARMP's revenue and growth?
Armata Pharmaceuticals, Inc. reported revenue of $31.0K.
Does ARMP pay dividends?
Armata Pharmaceuticals, Inc. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find ARMP SEC filings?
Official SEC filings for Armata Pharmaceuticals, Inc. (CIK: 0000921114) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARMP's EPS?
Armata Pharmaceuticals, Inc. has a diluted EPS of $-3.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ARMP's fundamental grade?
Based on our AI fundamental analysis in June 2026, Armata Pharmaceuticals, Inc. has a D grade with 96% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ARMP stock overvalued or undervalued?
Valuation metrics for ARMP: ROE of N/A (sector avg: 15%), net margin of -372,083.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ARMP's AI grade for 2026?
Our dual AI analysis gives Armata Pharmaceuticals, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARMP's free cash flow?
Armata Pharmaceuticals, Inc.'s operating cash flow is $-5.8M, with capital expenditures of $63.0K. FCF margin is -18,854.8%.
How does ARMP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -372,083.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.64 (avg: 2).